CXCR2 and prostate cancer: AZD5069 is a novel antagonist of CXCR2, which is shown to inhibit the binding of IL‐8 to CXCR2 specifically and is being investigated for the clinical benefits in combination with Enzalutamide in metastatic castration‐resistant prostate cancer patients (NCT03177187).